Inventor
ALVEY LUKE JONATHAN
FR19 patents
⚠️ This page may combine multiple inventors who share the name “ALVEY LUKE JONATHAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GALAPAGOS NV
13 patentsUS9255095B2Feb 9, 2016
Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GALAPAGOS NV6 citations82
US8927543B2Jan 6, 2015
Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GALAPAGOS NV6 citations82
US9926281B2Mar 27, 2018
5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
GALAPAGOS NV6 citations81
US10047083B2Aug 14, 2018
Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GALAPAGOS NV2 citations71
US10487060B2Nov 26, 2019
5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
GALAPAGOS NV4 citations70
US11339166B2May 24, 2022
Compounds and pharmaceutical compositions thereof for the treatment of diseases
GALAPAGOS NV2 citations68
US11220499B2Jan 11, 2022
Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GALAPAGOS NV0 citations60
US11718588B2Aug 8, 2023
5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
GALAPAGOS NV0 citations59
US10941117B2Mar 9, 2021
5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
GALAPAGOS NV0 citations59
US12065443B2Aug 20, 2024
Compounds and pharmaceutical compositions thereof for the treatment of diseases
GALAPAGOS NV0 citations58
US9708312B2Jul 18, 2017
Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (GPR84 antagonists)
GALAPAGOS NV1 citations50
US10829478B2Nov 10, 2020
5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis
GALAPAGOS NV0 citations37
US10550100B2Feb 4, 2020
5-[3-[piperzin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating E.G. osteoarthritis
GALAPAGOS NV0 citations37
ABBVIE SARL
4 patentsUS10259810B2Apr 16, 2019
N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
ABBVIE SARL5 citations82
US9890158B2Feb 13, 2018
N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
ABBVIE SARL5 citations81
US10647717B2May 12, 2020
N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
ABBVIE SARL1 citations71
US10130622B2Nov 20, 2018
Compounds for treatment of cystic fibrosis
ABBVIE SARL0 citations37